05-22-2023 | NEAR: IRTC | Press Release iRhythm Technologies Inc. (2023)

The clinical studies presented at Heart Rhythm 2023 build on the body of clinical evidence that continues to highlight the value of iRhythm's Zio products and services in a wide range of patient populations.

SAN FRANCISCO, May 22, 2023 (GLOBE NEWSWIRE) --Rhythm Technologies, Inc.(NASDAQ:IRTC), a leading digital health company focused on creating trusted solutions that detect, predict and prevent disease, today announced the presentation of four studies at the Heart Rhythm Society Annual Meeting, Heart Rhythm 2023, in New Orleans, THERE. These new data strengthen the body of clinical evidence that long-term ambulatory cardiac monitoring of up to 14 days with Zio®XT increases diagnostic throughput and improves diagnostic accuracy of ventricular arrhythmias in a wide range of patient populations.

This new scientific data from iRhythm builds on the body of clinical evidence – including real-world comparative effectiveness and comparative studies – that continues to highlight the value of iRhythm's Zio products and services.

Life-threatening ventricular arrhythmias, especially ventricular tachycardia and ventricular fibrillation, cause approx.300,000 deaths per year in the USand is responsible for nearly half of deaths from cardiac causes. Early detection and diagnosis are essential to treat these arrhythmias and prevent adverse health outcomes.

"These studies thematically demonstrate the value of iRhythm's Zio products and services - particularly in identifying ventricular arrhythmias for risk stratification and disease management," said Mintu Turakhia, MD, MAS, Chief Medical Officer, Chief Scientific Officer and Executive Vice President of iRhythm Product Innovation "The results have important clinical and scientific implications and further demonstrate the power of our technology across the full range of clinical arrhythmias."

Extended ambulatory ECG monitoring improves identification of high-risk patients with hypertrophic cardiomyopathy

The EXAMINE-HCM study showed that in patients with hypertrophic cardiomyopathy (HCM) -a heart condition that affects 1 in 500 people in the United States.which can lead to an increased risk of sudden cardiac death – long-term monitoring of up to 14 days with the Zio XT service significantly improves the diagnostic yield of non-sustained ventricular tachycardia (NSVT). This can be of great importance to assess the risk of arrhythmias and define treatment options in these patients.

(Video) CEO Bill Willis on how iRhythm Technologies' diagnostic devices improve patient's lives

Main conclusions:

  • The diagnostic yield for detecting NSVT was significantly increased using 14 days of surveillance, with 48 hours of surveillance missing nearly two-thirds of patients with high-risk NSVT episodes, which may influence risk stratification and treatment.
  • The diagnostic yield of NSVT detection was 18% during the first 48 hours of monitoring, compared to 48% after 14 days, with 63% of initial episodes of NSVT occurring after the first 48 hours.
  • The diagnostic yield of detecting high-risk NSVT episodes was 8% during the first 48 hours compared to 24% at 14 days, with 64% of the initial high-risk NSVT runs occurring after the first 48 hours.

The PVC Load Analysis Study: Premature Ventricular Complexes (PVC): Evaluation of Load Density in a Large National Cohort Population to Better Define the Optimal Duration of ECG Monitoring

The PVC Burden Analysis Study of 106,705 patients shows that increased monitoring for at least seven to 10 days in duration is associated with greater accuracy in categorizing patients by level of PVC burden. The results are important, as classification errors can affect clinical decision-making.

Main conclusions:

  • An estimate of 48 hours of PVC misclassified PVC burden compared with 14 days of ambulatory ECG monitoring.
  • At least seven days of continuous ambulatory ECG monitoring performed by the Zio service were required to achieve >95% accuracy in load categorization.

The prognostic study of non-sustained VT: practical variation after ambulatory ECG detection of non-sustained ventricular tachycardia in the non-cardiac patient

In the Nonsustained VT Prognosis Study, a retrospective study by the Veterans Health Administration, the largest integrated health care system in the United States, nearly one-third of the 58,279 patients who received long-term ambulatory ECG monitoring for up to 14 days with Zio had NSVT . The results highlight the possibility of creating risk models and integrated treatment pathways after ambulatory ECG monitoring.

(Video) Bought $IRTC ( irhythm tech ) today - My Full Research here ( Feb 16, 2021)

Main conclusions:

  • There was wide local variation in diagnostic tests and treatment in the VA Health Care System after detection of NSVT, such as in the proportion of patients with echocardiograms, coronary angiograms, stress tests, cardiologic treatment, and use of cardiovascular medications in the 90-day post-follow-up period outpatient.

Flec-ARVC Trial: Randomized Placebo-Controlled Trial of Flecainide in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy

The Flec-ARVC study, conducted at the University of Rochester, the Johns Hopkins ARVC Program and at other institutions outside of iRhythm, is the first randomized clinical trial evaluating flecainide in arrhythmogenic right ventricular cardiomyopathy (ARVC). ARVC is an inherited heart disease that carries a high risk of ventricular tachycardia and sudden death, often in young people. Although implantable cardioverter defibrillators (ICDs) can prevent sudden cardiac death, recurrent ventricular arrhythmias can be a significant clinical challenge, and there is limited data from studies on the effectiveness of antiarrhythmic therapy for suppression of ventricular arrhythmia. Using Zio Services highlights Zio's PVC load measurement capabilities and, more generally, the ability to use Zio Service in clinical trials and research.

Main conclusions:

  • In this randomized, placebo-controlled, crossover study of 41 patients who received Zio XT ambulatory ECG monitoring for seven days, Flecainide significantly reduced CVP burden.

About the study "Extended ambulatory ECG monitoring improves identification of high-risk patients with hypertrophic cardiomyopathy"
Forfater: Ethan J. Rowin, MD; Gaurav Das, MD; Christopher Madias, MD; Mike Hsu, PhD; Lori Crosson, PhD; Barry J. Maron, MD; Mintu P. Turakhia, MD, MAS; Martin S. Maron, MD

Study authors evaluated 236 patients with hypertrophic cardiomyopathy (HCM) (49 ± 12 years; 72% male) without a primary prevention implantable cardioverter-defibrillator previously assessed as having low or intermediate risk of sudden death (SD) with continuous ambulatory monitoring of 14 days Zio XT . NSVT episodes were evaluated during the first 48 hours of monitoring and compared with NSVT identified in the subsequent two to 14 days. NSVT episodes with ≥1 of the following criteria were considered higher risk as a marker of DS: ≥ 200 beats per minute, ≥ eight beats, ≥ three runs in a consecutive 48-hour period. Among the 236 patients, 114 (48%) had ≥ one cycle of NSVT, with a median of two cycles (IQR: 1-4) during the entire monitoring period, including 86 patients with ≤ four cycles (36%), 13 with five to nine runs (6%) and 15 with ≥10 runs (7%). The diagnostic yield of NSVT detection was 18% during the first 48 hours of monitoring compared to 48% after 14 days, with 63% of initial NSVT episodes occurring after the first 48 hours (72 of 114). Likewise, the diagnostic yield of detecting high-risk NSVT episodes was 8% during the first 48 hours compared to 24% at 14 days, with 64% of the initial runs of high-risk NSVT occurring after the first 48 hours. hours (36 out of 56).

(Video) Stock Charts: CAR, CRSP, IRTC, OTRK, QTRX, YRCW

Om "Premature Ventrikulære Complexes: Assessing loading density in a large national cohort population to better define the optimal duration of ECG monitoring" undersøgelse
Forfater: Andrew Krumerman, MD; Luigi Di Biase, MD, PhD; Jay J. Chudow, MD; Ardit Kacorri, MD; Lori Crosson, PhD; Alan Wilk, BS; Kevin J. Ferrick, MD

Patients with a PVC burden ≥5%, age ≥18, and a period of use of ≥13 days were analyzed between June 2011 and April 2022. Patient demographics were reported and the mean absolute error in PVC burden was calculated at baseline (<10 sec.), 24 hours, 48 ​​hours, and daily for 14 days. The load at the end of the wear period was taken as the true value for the PVC load. The measured error was described for each subinterval (mean, SD, median, IQR). PVC loading accuracy was evaluated at monitoring durations at thresholds of 10% (low), 15% (moderate), and 20% (high). 106,705 patients were analyzed. PVC density was more frequent in men than in women, 66:34, and in those over 65 years old, respectively. Mean absolute error for CVP load was calculated at baseline (<10 sec), 24 hours, 48 ​​hours, seven days, and 13 days (Figure 1). When comparing PVC load densities of less than and greater than 20% at 24 hours and 7 days, the data showed a decrease in mean absolute error from 2.78% and 3.97% at 24 hours to 1.27% and 1. 75% after seven days. Furthermore, the accuracy in classifying the PVC load within a 15% threshold increased from 89.2% after 24 hours to 95.1% after seven days.

About the study "Practical variation after ambulatory ECG detection of non-sustained ventricular tachycardia in non-cardiac patients"
Author: Krishna Pundi, MD; June Fan, MS; Natasha Dean, MBBS, MA; Alex T. Sandhu, MD, MS; Paul A. Heidenreich, MD, MS; Mintu Turakhia MD, MAS

The authors conducted a retrospective cohort study using data from the Veterans Health Administration, the largest integrated health care system in the United States. They included patients who received a Zio XT monitor between 11/18/2011 and 6/23/2020 and excluded patients with a history of arrhythmias, atherosclerotic disease, or heart failure. The authors defined NSVT as at least one VT episode ≥3 beats but <30 seconds in duration. They determined healthcare utilization and drug prescriptions within 90 days of the Zio monitor and examined variation in treatment at the site level. The authors analyzed 58,279 patients with no known heart disease, of which 18,792 (32.2%) had NSVT. They matched 18,263 NSVT patients (97.2%) at 89 unique sites for site-level analysis. There was considerable local variation in the proportion of patients with echocardiograms, coronary angiograms, stress tests, cardiologic treatment, and prescriptions filled within 90 days of monitoring. After adjusting for baseline characteristics and medications, the authors found only significant associations between the Charlson comorbidity index and the use of echocardiography (odds ratio [OR]: 0.95, 95% confidence interval [CI]: 0, 91-0.99, p=0.008), age and stress test (OR 0.92, 95% CI: 0.88-0.95, p<0.0001) and high-volume sites and cardiac treatment (OR 1.83, 95% CI: 1.16-2.89, p=0.01).

About the Study "Randomized Placebo-Controlled Trial of Flecainide in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy"
Forfattere: Wojciech Zareba, MD, PhD; Crystal Tichnell, MS; Spencer Z. Rosero, MD; marineCerrone , MD ; Matthew M. Zipse, MD; Francis E. Marchlinski, MD; Albert Y. Sun, PhD; Julia H. Indick, MD, PhD; Cynthia A. James, PhD; Luisa Mestroni, MD; Kristina Cutter; Derick R. Peterson, PhD; Scott McNitt, MS; Bronislava Polonsky, MS; James P. Daubert, MD; Mark C. Haigney, MD; Matthew Needleman, MBA; David Oakes, PhD; Mario Delmar, MD, PhD; Hugh Calkins, physician

Study authors conducted an NIH-funded pilot clinical trial hypothesizing that administration of flecainide is more effective than placebo in reducing the burden of ventricular premature beats (VPBs) in patients with ARVC. The study was designed as a randomized, double-blind, placebo-controlled crossover study in patients with ARVC given flecainide 100 mg twice daily or matching placebo for four weeks each with a washout period. The primary specific objective was to determine whether flecainide administration is associated with a significant reduction in BPVs compared with placebo, as measured by 7-day Zio patch monitoring. The mean and median number of BPVs/day were significantly lower with flecainide than with placebo. A reduction of at least 50% in BPVs/day was seen in 79% and a reduction of at least 75% in 53% of patients. The primary analysis showed that flecainide reduced the rate of BPV by 72% (p < 0.0001, 95% CI: 56–82%), adjusted for period effect. The study concluded that flecainide significantly reduced the BPV rate and the NSVT/VT/VF rate, supporting the clinical use of this medication in patients with ARVC.

(Video) Developers, users of digital health technologies must first identify unmet needs to address

To learn more about iRhythm, including its portfolio of Zio products and services, visitirhythmtech.com.

Om iRhythm Technologies, Inc.
iRhythm is a leading digital health company that creates trusted solutions that detect, predict and prevent disease. By combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm's vision is to provide better data, better insights and better health for all.

Investor Relations Contact:
Stephanie Zhadkevitj
(919) 452-5430

Counted by iRhythm Media:
Morgan Mathis
(310) 528-6306

05-22-2023 | NEAR: IRTC | Press Release iRhythm Technologies Inc. (1)
05-22-2023 | NEAR: IRTC | Press Release iRhythm Technologies Inc. (2)

05-22-2023 | NEAR: IRTC | Press Release iRhythm Technologies Inc. (3)

(Video) BDSI - BioDelivery Sciences - Is BDSI a Stock to Buy Now? - [Due Diligence] [DD] as of 11/13/2021


What is iRhythm target price? ›

iRhythm Technologies Inc (NASDAQ:IRTC)

The 9 analysts offering 12-month price forecasts for iRhythm Technologies Inc have a median target of 150.00, with a high estimate of 170.00 and a low estimate of 130.00. The median estimate represents a +15.17% increase from the last price of 130.24.

Is iRhythm a good company? ›

Is iRhythm Technologies a good company to work for? iRhythm Technologies has an overall rating of 3.4 out of 5, based on over 191 reviews left anonymously by employees. 51% of employees would recommend working at iRhythm Technologies to a friend and 54% have a positive outlook for the business.

How can I get my Zio patch results? ›

iRhythm. The patient list displays all the patient reports pertaining to the Zio® XT Patch and can be accessed by navigating to Patient → Patient List.

How much does a Zio patch cost? ›

The Zio patch is more expensive than older monitors: about $360 for Medicare versus $100 to $150 for Holter monitors, King said. The higher price can occasionally cause trouble with insurance reimbursement, though Gerstenfeld estimated about 80 percent of insurance companies cover the patch.

Is iRhythm FDA approved? ›

iRhythm Gains FDA Clearance for its Clinically Integrated ZEUS System.

What is the target price for eyes stock? ›

National Vision Holdings Inc (NASDAQ:EYE)

The 11 analysts offering 12-month price forecasts for National Vision Holdings Inc have a median target of 28.00, with a high estimate of 38.00 and a low estimate of 20.00. The median estimate represents a +16.38% increase from the last price of 24.06.

Who are competitors of iRhythm? ›

Top 10 iRhythm Technologies competitors
  • Preventice Solutions.
  • Bardy Diagnostics.
  • Peerbridge Health.
  • Byteflies.
  • AliveCor.
  • SEERS Technology.
  • Wellysis.

What is the new product of iRhythm? ›

May 25, 2021 — iRhythm Technologies Inc. announced two new U.S. Food and Drug Administration (FDA) 510(k) clearances — one for a new and improved design of its flagship Zio wearable cardiac monitor, and a second for updated artificial intelligence (AI) capabilities.

Who is iRhythm owned by? ›

iRhythm Technologies Inc (NASDAQ:IRTC)

Institutional investors hold a majority ownership of IRTC through the 110.93% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Medical Specialties industry.

Does the Zio patch record everything? ›

The Zio ambulatory cardiac monitor is a small, unobtrusive, and water-resistant patch—you might even forget you're wearing it. The Zio monitor records and stores every beat of your heart, whether you're sleeping, working out, or showering.

Does Zio record all the time? ›

Zio is a prescription-only, single patient use, continuously recording ECG monitoring system that can be worn for up to 14 days.

What can you not do while wearing a heart monitor? ›

Don't take the Holter monitor off — it must be worn during the entire recording period, even while sleeping. Water can damage a Holter monitor. Don't swim, shower or bathe for the entire time you're wearing a Holter monitor.

How much does a 7 day Zio patch cost? ›

The Zio patch is already on the market to check for a range of irregular heart conditions. It has a U.S. list price of $995 and is covered by most major insurers, according to the company.

What are the side effects of Zio heart monitor? ›

Patient may experience skin irritation. If skin irritation such as severe redness, itching or allergic symptoms develop, remove the zio xt patch from the patient's chest. The patient presented to their healthcare provider with a probable contact dermatitis where treatment was prescribed.

What can you not do with a Zio patch? ›

What activities should I avoid? Activities that cause excessive sweating can cause the ZIO® XT Patch to slide, become loose, fall off, and shorten wear time.

Can you get an MRI with a Zio patch? ›

The following are not recommended during wear of the Zio monitor: Magnetic Field(s): Magnetic Resonance Imaging (MRI); MRI Technician; Any job where the patient may be exposed to a large magnetic field.

Is Zio patch better than heart monitor? ›

A Holter monitor is a battery-operated portable device that measures and records your heart's electrical activity (ECG) continuously. Patients in this study will wear the monitor for 48 hours. The Zio Patch is a small, adhesive, water-resistant single lead electrocardiographic monitoring device.

How accurate is Zio? ›

The monitor

diagnostic yield. Zio XT is as accurate as the gold standard at detecting AF burden. Patients are 98% compliant with Zio because the wear experience is easy, and no manipulations are required.

What is best stock price target? ›


The 1 analysts offering 12-month price forecasts for BEST Inc have a median target of 12.52, with a high estimate of 12.52 and a low estimate of 12.52.

What was the highest target stock price? ›

Historical daily share price chart and data for Target since 1983 adjusted for splits. The latest closing stock price for Target as of May 19, 2023 is 152.28. The all-time high Target stock closing price was 257.58 on November 16, 2021.

Is eyes stock a good buy? ›

The financial health and growth prospects of EYE, demonstrate its potential to outperform the market. It currently has a Growth Score of B. Recent price changes and earnings estimate revisions indicate this would not be a good stock for momentum investors with a Momentum Score of D.

How many people work at iRhythm? ›

iRhythm Technologies is a medium health care company with 400 employees and an annual revenue of $265.2M that is headquartered in San Francisco, CA.

What type of company is iRhythm? ›

iRhythm is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and machine- learning capabilities.

How much is iRhythm? ›

Performance Outlook
Previous Close130.04
Day's Range124.76 - 131.87
52 Week Range85.74 - 164.69
Avg. Volume323,332
3 more rows

How long has iRhythm been around? ›

Uday N. Kumar founded iRhythm out of the Biodesign Innovation Fellowship in 2006.

How long has iRhythm been in business? ›

More about iRhythm

Founded in 2008, the San Francisco–based company seeks to usurp the old-school Holter monitor for electrocardiograph monitoring and AFib detection.

When did iRhythm go public? ›

The company's shares are expected to begin trading on NASDAQ on October 20, 2016 under the ticker symbol "IRTC."

Is iRhythm a public company? ›

iRhythm will hold its annual meetings as a public company at its principal executive office at 699 8th St., Suite 600, San Francisco, CA 94103 on a yearly basis.

Who are Zio competitors? ›

Zio lists Philips' BioTelemetry, Boston Scientific's Preventice Solutions and Baxter's Bardy Diagnostics as the competitors to its Zio services.

What is iRhythm market size? ›

Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. IRhythm Technologies market cap as of May 10, 2023 is $3.9B.

Does the Zio patch light up? ›

You should have seen a brief green flash after pushing the Zio button when first attaching the patch, which means it is working. After this the Zio Patch will not flash or make a noise if all is well. If you would like to check press and hold the Zio button until the brief green flash occurs (~10 seconds).

What happens if you take a shower with my zio? ›

You may continue your normal activities while wearing Zio including showering and exercising. There are, however, a few things to keep in mind to ensure the monitor doesn't slip or fall off.

Can I take my Zio patch off and put it back on? ›

No, if the Zio Patch is over the heart in a slight diagonal as shown the positioning should be acceptable. DO NOT attempt to reapply the Zio Patch.

How many leads does Zio patch have? ›

The Zio Patch has 1 lead versus the 12 leads of the Holter monitor, which may impact the detection rate of the patch.

How long can you wear Zio monitor? ›

Zio XT heart rhythm monitor is a patch that can be worn for up to 14 days on your chest.

What data does Zio patch collect? ›

It's water resistant and can be kept on around the clock while a person sleeps, exercises, or takes a shower. The wireless patch continuously monitors heart rhythms, storing EKG data for later analysis. The Stanford researchers looked to machine learning to process all the EKG data.

Can a heart monitor detect anxiety? ›

A heart monitor is a small device that records heart rhythm day and night or during active symptoms. Capturing heart rhythm over several days or weeks, a doctor can accurately determine which comes first, anxiety or abnormal beats.

Will a cell phone interfere with a heart monitor? ›

Keep everyday electronic items at least 6 inches away from the heart monitoring device. Don't use any electronic item that might interfere with the signals of the device.

What is the best way to sleep with a heart monitor? ›

In fact, sleeping on your side is the best position to sleep in with a Holter monitor attached to your chest. This is because it's important to keep the monitoring device close to your chest when you sleep. Plus, when you sleep on your side, it prevents the electrodes and wires from getting snagged or pulled out.

Does Zio Patch record heart rate? ›

The Zio monitor is a small, discreet, comfortable patch that you will apply to the left side of your chest. It will monitor your heart rhythm during your normal day-to-day activity, including while you sleep, shower, and exercise, while it records every single heartbeat for analysis.

Why is my Zio patch flashing orange after I take it off? ›

An orange flash means that the patch is not well attached. Apply continuous pressure across two sticky pads for 2 minutes to try and re-adhere it. If the Zio Patch continues to flash orange, call the clinical trials support team for further advice.

Can Zio patch detect ischemia? ›

Our findings showed that the Zio Patch was worn by stroke and transient ischaemic attack patients for long periods of time, and that it identified a significant number of arrhythmia events that would have been missed by traditional Holter monitors, due to their shorter wear times.”

Is iRhythm profitable? ›

For the last half decade, iRhythm Technologies can boast revenue growth at a rate of 25% per year. That's well above most pre-profit companies. Meanwhile, its share price performance certainly reflects the strong growth, given the share price grew at 16% per year, compound, during the period.

What companies are similar to iRhythm? ›

Top 10 iRhythm Technologies competitors
  • Preventice Solutions.
  • Bardy Diagnostics.
  • Byteflies.
  • Peerbridge Health.
  • AliveCor.
  • SEERS Technology.
  • Wellysis.

Should I buy IRTC? ›

Irhythm Technologies Stock Forecast FAQ

Out of 7 analysts, 5 (71.43%) are recommending IRTC as a Strong Buy, 1 (14.29%) are recommending IRTC as a Buy, 1 (14.29%) are recommending IRTC as a Hold, 0 (0%) are recommending IRTC as a Sell, and 0 (0%) are recommending IRTC as a Strong Sell.

Why is iRhythm stock dropping? ›

iRhythm Technologies (NASDAQ:IRTC) Drops After Business Update. iRhythm Technologies (NASDAQ:IRTC) shares are tanking in the trade today after an update on its guidance for 2022. The digital health care company is eyeing $1+ billion in revenues by 2027. It has reiterated its earlier guidance for 2022.

How much does a Director at iRhythm make? ›

$362,695. The estimated total pay for a Director at iRhythm Technologies is $362,695 per year.

How much does a quality specialist at iRhythm make? ›

The base salary for Entry Quality Assurance Specialist in companies like IRHYTHM TECHNOLOGIES INC range from $72,500 to $90,700 with the average base salary of $81,900.

What is the NPI for iRhythm Technologies? ›

The diagnostic test is performed by iRhythm Technologies, Inc. National Provider Identification (NPI) # is 1710130539.

What is the best railroad to invest in? ›

Best Value Railroad Stocks
Price ($)12-Month Trailing P/E Ratio
Norfolk Southern Corp. (NSC)206.3214.8
CSX Corp. (CSX)30.1615.5
Union Pacific Corp. (UNP)198.7317.7
Apr 24, 2023

Which shares are best to buy today? ›

Stocks to Buy Today
1 more row

Is Trainline a buy? ›

The overall consensus recommendation for Trainline is Buy.


1. AQMS, NRG, PLAY, TREE — Harry Boxer, TheTechTrader.com
(Harry Boxer - TheTechTrader)
2. CORT, HIIQ, GKOS, XEC - Harry Boxer, TheTechTrader.com
(Harry Boxer - TheTechTrader)
3. Inflation Surges, Bond Market Yawns | Tom Bowley | Trading Places (07.14.22)
(StockCharts TV)
4. How To Create Stock Watchlist In Under 10 Mins
(Blueprint Skillz)
(Madeline & Penelope Capital)
6. $PYTK Playtika IPO Stock Market Trade
(Andrew Abraham)
Top Articles
Latest Posts
Article information

Author: Tyson Zemlak

Last Updated: 06/03/2023

Views: 6075

Rating: 4.2 / 5 (63 voted)

Reviews: 86% of readers found this page helpful

Author information

Name: Tyson Zemlak

Birthday: 1992-03-17

Address: Apt. 662 96191 Quigley Dam, Kubview, MA 42013

Phone: +441678032891

Job: Community-Services Orchestrator

Hobby: Coffee roasting, Calligraphy, Metalworking, Fashion, Vehicle restoration, Shopping, Photography

Introduction: My name is Tyson Zemlak, I am a excited, light, sparkling, super, open, fair, magnificent person who loves writing and wants to share my knowledge and understanding with you.